Interpreting Biomarker Discordance in Inflammatory Bowel Disease: Beyond Fecal Calprotectin and C-Reactive Protein. (PubMed, Biomedicines) - Sep 27, 2026 - "Vedolizumab and ustekinumab show exposure-response associations, but actionable thresholds are unvalidated, and clinical TDM is not established for newer biologics or oral small molecules. Clinically important disagreement should prompt assessment of sampling, assay, timing, infection, medication-related confounding, and pretest probability before phenotype-directed endoscopy, histology, imaging, or reactive TDM is selected. A single discordant result should neither trigger treatment escalation nor exclude active or structural disease."
Biomarker • Journal • Review • Fibrosis • Gastroenterology • Gastrointestinal Disorder • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Oncology • CRP • LRG1
|
|
Dinko Martinovic; Josko Bozic; Lovre Martinovic; Marino Vilovic; Marko Kumric; Roko Santic
|